NuScale Power’s small modular reactor (SMR) unit maintains a long‐dated project pipeline, with seven reactor modules under contract in the U.K. and Poland representing a combined capacity of 462 MW. While the design received U.S. Nuclear Regulatory Commission certification in 2024—the first SMR to do so—commercial operations are not expected until 2028 for the first four‐module site in Idaho. Subsequent projects, including a six‐module plant in Poland slated for 2030, hinge on final government funding approvals and consortium financing agreements that remain under negotiation.

As of Q3 2025, NuScale reported cash and equivalents of $210 million, supporting R&D and licensing through mid‐2026. However, estimated capital expenditures of $350 million for final construction engineering and site preparation signal potential dilution risks if additional equity raises are required. Management anticipates securing a $500 million project finance facility by year‐end to underwrite initial module fabrication, with debt service commencing in 2029 once commercial operations begin.

NuScale’s firm contract backlog stood at $1.2 billion as of December 2025, driven by multi‐year agreements with U.S. federal agencies and European utilities. Revenue recognition for engineering, procurement and construction (EPC) services is scheduled to start in late 2027, with full module delivery payments back‐loaded to 2032. While these contracts underpin long‐term revenue visibility, they expose the company to performance guarantee penalties of up to 10% of contract value if milestone deadlines slip.

Investors face a binary outcome: successful first‐of‐a‐kind deployment could validate NuScale’s scalable SMR model and unlock follow-on projects worth an estimated $8 billion over the next decade, whereas further delays or cost overruns could deplete cash reserves and trigger down rounds. Analysts project the firm to reach break-even by 2030, assuming steady module order flow and no material escalation in component costs. Given the high execution leverage, SMR stock should be considered a high-beta play on advanced nuclear commercialization rather than a stable income generator.